Bernie Sanders Calls Out Zika Vaccine Maker And Trump
The French pharmaceutical company, Sanofi Pasteur, has began it’s process of fleecing the American public. The company has recieved $34 million dollars in research grants from the Department of Health and Human Services, based on a deal whereas the Army will do an exclusive deal with Sanofi over the rights to distribute the vaccine.
But as soon as the Army asked Sanofi Pasteur to price the Zika vaccine in an affordable manner, the Army learned a tough lesson about pharma: They do what benefits them the most. The company is refusing to meet pricing requests by the Army, even after taking the millions in taxpayer money. Yes, this means we the people funded a vaccine that seems hardly nessecary and now in addition, the recipient of our hard earned money plans to price gouge us.
Worse more? President Trump may just allow this fleecing to take place. And this has caused Vermont Senator, Bernie Sanders, to sound off and plea with the President to stop this scam.
“Now his administration, through the Army, is on the brink of making a bad deal, giving French Pharmaceutical company, Sanofi, the exclusive license to patents and thus a monopoly to sell a vaccine against Zika virus.” Sanders wrote in a NYTimes article back in March. “If Mr. Trump allows this deal, Sanofi will be able to charge whatever astronomical price it wants for its vaccine. Millions of people in the United States and around the world will not be able to afford it even though American taxpayers have already spent more than $1 billion on Zika research and prevention efforts, including millions to develop this vaccine.”
The Army’s intention to offer Sanofi Pastuer exclusive rights to the vaccine has massively backfired, causing embarrasment for the Department of Defense and anger for lawmakers even beyond Sanders. It would seem our Army officials underestimated the level of pharmaceutical greed and now they’ve backed themselves into a corner.
Worse more, pharma now wants to test an experimental DNA vaccine for the virus. A new clinical trial is set to begin soon. In South Florida, the clinical trial will take place at the University of Miami Miller School of Medicine, with Margaret Fischl, a UM infectious disease physician and scientist, as the principal investigator responsible for conducting daily reviews of safety data.
Photo by ScottP-Photography
Author: Jim Satney
PrepForThat’s Editor and lead writer for political, survival, and weather categories.
*As an Amazon Associate I earn from qualifying purchases
Like Us On Facebook -